

SUPPLEMENTARY MATERIALS

Treatment pathway and clinical outcomes of the population with muscle-invasive bladder cancer in Italy: a real-world analysis with administrative databases

Paolo Luraghi^{2x}, Valentina Perrone^{1x}, Daniela Castelletti², Serena Losi², Matteo Risi², Stefania Mazzoni¹, Luca Degli Esposti¹, Lorenzo Antonuzzo³

¹*CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Bologna, Italia.*

²*Department of Medical Oncology, AstraZeneca, Milan, Italy.*

³*Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Azienda Ospedaliera Universitaria Careggi, Clinical Oncology, Florence, Italy.*

^x *equally contributed*

Corresponding author: Valentina Perrone, CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Via Murri 9, 40137 Bologna, Italy. Phone: +39 (0)544 38393; Fax: +39 (0)544 212699; E-mail: valentina.perrone@clicon.it




Figure S1. (A) Overall survival; (B) Disease-free survival; and (C) Time-to-progression in patients with MIBC stratified by treatment allocation.

Abbreviations: CI, confidence interval; CrCl, creatinine clearance; DFS, disease-free survival survival; MIBC, muscle-invasive bladder cancer; OS, disease-free survival survival.